George Ansstas, MD

Medical Oncologist, Neuro-Oncologist

George Ansstas

Appointment Options

Whether you’re seeking a new patient appointment or exploring treatment options and looking for a second opinion, our Siteman care coordinators are ready to assist you.

My Locations

Gary C. Werths Building at Siteman Cancer Center

Gary C. Werths Building at Siteman Cancer Center

On WashU Medicine Campus
4500 Forest Park Avenue, Saint Louis, MO 63108
Siteman Cancer Center at Barnes-Jewish West County Hospital

Siteman Cancer Center at Barnes-Jewish West County Hospital

Medical Office Building 2, 10 Barnes West Drive, Creve Coeur, MO 63141

Expertise & Training

Video thumbnail for George Ansstas, MD

Watch video on YouTube

George Ansstas, MD

2 mins

Washington University medical and neuro-oncologist, George Ansstas, MD, discusses what patients with brain tumors, skin cancer and melanoma can expect from their extended care team at Siteman Cancer Center. Learn more about Dr. Ansstas: https://siteman.wustl.edu/doctor/ansstas-george/

Explore the Brain Tumor Center at Siteman: https://siteman.wustl.edu/treatment/cancer-types/brain-tumor-center/

Learn more about how Siteman personalizes brain tumor treatment: https://siteman.wustl.edu/personalized-brain-tumor-treatment/

Learn more about the Siteman Approach to Skin Cancer: https://siteman.wustl.edu/treatment/cancer-types/skin/our-approach/

Clinical Expertise

  • As a member of our brain tumor and skin cancer specialist teams, Dr. Ansstas cares for patients diagnosed with brain tumors, skin cancer & melanoma through treatment and recovery. Learn more about Dr. Ansstas and the Brain Tumor Center at Siteman.

Primary Academic Title

Professor of Medicine, Section of Medical Oncology, Division of Oncology, WashU Medicine

Board Certification

  • 2007: American Board of Internal Medicine
  • 2011: American Board of Internal Medicine, Medical Oncology
  • 2011: American Board of Internal Medicine, Hematology

Training

  • 2001 - 2003: Resident, Anatomic and Clinical Pathology, Tishreen University Hospital, Lattakia, Syria
  • 2004 - 2007: Resident, Internal Medicine, Saint Louis University Medical Center, St. Louis, MO
  • 2008 - 2011: Fellow, Hematology and Oncology, WashU Medicine, St. Louis, MO

Education

  • 2001: MD, University of Tishreen, Latakia, Syria

Research & Selected Publications

Research Interest

Glioblastoma, genetics and epigenetics, melanoma

Research Publications

Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Authors:

Ansstas G, Khaddour K, Sudhaman S, one or more additional authors omitted Tan A

Journal & Year:

Clin Cancer Res | 2026

Interobserver variability in histopathologic diagnosis of melanocytic neoplasms
Authors:

Alexander NA, Park M, Shin H, one or more additional authors omitted Ansstas G, one or more additional authors omitted Chen DY

Journal & Year:

J Am Acad Dermatol | 2026

Laser interstitial thermal therapy and adjuvant pembrolizumab in recurrent high-grade astrocytoma: a Phase 1/randomized Phase 2b trial
Authors:

Campian JL, Le SB, Ghiaseddin A, one or more additional authors omitted Ansstas G, one or more additional authors omitted Tran DD

Journal & Year:

Nat Commun | 2026

Homologous Recombination Deficiency in Skin Cancers: Prevalence and Clinical Implications of This Distinct Patient Cohort
Authors:

Nassief G, Adeyelu T, Elliott A, one or more additional authors omitted Ansstas G

Journal & Year:

JCO Precis Oncol | 2026

Real-world outcomes of talimogene laherparepvec as salvage therapy for advanced melanoma
Authors:

Yamada MM, Chandrasekhar S, Gooley TA, one or more additional authors omitted Ansstas G, one or more additional authors omitted Chen DY

Journal & Year:

J Immunother Cancer | 2025

Targeted therapies and PARPi therapy response following ICI therapy failure in advanced melanoma: a case series
Authors:

Nassief G, Morecroft R, Phillipps J, Chen D, Ansstas G

Journal & Year:

Melanoma Manag | 2025

Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors
Authors:

Milhem MM, Wise-Draper TM, Chandra S, one or more additional authors omitted Ansstas G, one or more additional authors omitted Bhatia S

Journal & Year:

J Immunother Cancer | 2025

A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary a…
Authors:

Hughes BGM, Guminski A, Bowyer S, one or more additional authors omitted Ansstas G, one or more additional authors omitted Rischin D

Journal & Year:

J Am Acad Dermatol | 2025